+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening for EGFR mutations in lung cancer, a report from India

Screening for EGFR mutations in lung cancer, a report from India

Lung Cancer 73(3): 316-319

Epidermal growth factor receptor (EGFR) is one of the targeted molecular markers in many cancers including the lung malignancy. Genetic modifications such as deletions, insertions and Single Nucleotide Polymorphisms in the tyrosine kinase (TK) domain of EGFR is a common feature observed in most lung cancers. Gefitinib and erlotinib are commonly available therapeutic drugs which act as specific inhibitors for the tyrosine kinase domain of EGFR and associated with EGFR mutations in exons 18-21. However the prevalence of mutation varies among ethnicity, grade, age and gender. This is the first report on the prevalence of EGFR mutation in non-small cell lung cancer patients using DNA obtained from samples such as biopsy/cytology/pleural fluid and Fine Needle Aspiration (FNA), across India. We have screened for 29 somatic mutations which span exons 18, 19, 20 and 21 of EGFR gene using Scorpion probe based ARMS-PCR technique. DNA from 220 NSCLC tissue samples were analyzed for EGFR mutations and mutations were detected in 51.8% of the study population. Among the mutant positive cases, the deletions in exon 19 (52%) and a missense mutation L858R in exon 21 (26%) were most predominant. There was a significant increase in overall mutations (p=0.01) as a function of age, mutation in exons 19 and 21 together (p=0.003), mutations in exons 18, 19 and 21 (p=0.04) and mutations in exons 18 and 19 (p=0.03) in females. Mutations did not seem to significantly correlate metastases or disease progression. Mutations in exons [19] and 21 together were significant in non-smokers compared to smokers (p=0.01) using Mann-Whitney tests. The study suggests high prevalence of EGFR positivity in NSCLC in Indian sub-population and provides opportunities for targeted therapies for this group.

(PDF emailed within 0-6 h: $19.90)

Accession: 055670749

Download citation: RISBibTeXText

PMID: 21315473

DOI: 10.1016/j.lungcan.2011.01.004

Related references

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations. Clinical Advances in Hematology & Oncology 14(1): 41, 44-5, 2016

Screening for EGFR mutations in lung cancer. Discovery Medicine 8(43): 181-184, 2010

EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature. Oncology Letters 11(5): 3546-3550, 2016

Screening for germline EGFR T790M mutations through lung cancer genotyping. Journal of Thoracic Oncology 7(6): 1049-1052, 2012

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients. Clinical Advances in Hematology & Oncology 14(1): 41-43, 2016

Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. European Respiratory Journal 38(4): 903-910, 2012

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73(1): 96-102, 2011

Screening for EGFR mutations in lung cancer by a novel real-time PCR with double-loop probe and Sanger DNA sequencing. Zhonghua Zhong Liu Za Zhi 35(1): 28-32, 2013

Frequency of EGFR mutations in non-small cell lung cancer patients: screening data from West Siberia. Asian Pacific Journal of Cancer Prevention 16(2): 689-692, 2015

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. Plos One 9(2): E88291-E88291, 2015

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. Journal of the National Comprehensive Cancer Network 12(1): 6-11; Quiz 11, 2014

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology 33(17): 1958-1965, 2015

Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. Plos One 6(9): E25191-E25191, 2012

EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report. Lung Cancer 49(3): 413-415, 2005

EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Seminars in Oncology Nursing 24(1): 27-33, 2008